These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 23550808

  • 1. The bioequivalence of the contraceptive steroids ethinylestradiol and drospirenone is not affected by co-administration of dehydroepiandrosterone.
    Zimmerman Y, Wouters W, Coelingh Bennink HJ.
    Eur J Contracept Reprod Health Care; 2013 Jun; 18(3):206-14. PubMed ID: 23550808
    [Abstract] [Full Text] [Related]

  • 2. The pharmacokinetics and pharmacodynamics of dehydroepiandrosterone during use of an ethinylestradiol- and drospirenone-containing oral contraceptive.
    Zimmerman Y, Coelingh Bennink HJ, Wouters W, Ebes F, Fauser BC.
    Eur J Contracept Reprod Health Care; 2013 Dec; 18(6):489-500. PubMed ID: 23944295
    [Abstract] [Full Text] [Related]

  • 3. Maintaining physiological testosterone levels by adding dehydroepiandrosterone to combined oral contraceptives: I. Endocrine effects.
    Coelingh Bennink HJT, Zimmerman Y, Laan E, Termeer HMM, Appels N, Albert A, Fauser BCJM, Thijssen JHH, van Lunsen RHW.
    Contraception; 2017 Nov; 96(5):322-329. PubMed ID: 27393080
    [Abstract] [Full Text] [Related]

  • 4. Restoring testosterone levels by adding dehydroepiandrosterone to a drospirenone containing combined oral contraceptive: I. Endocrine effects.
    Zimmerman Y, Foidart JM, Pintiaux A, Minon JM, Fauser BC, Cobey K, Coelingh Bennink HJ.
    Contraception; 2015 Feb; 91(2):127-33. PubMed ID: 25604900
    [Abstract] [Full Text] [Related]

  • 5. Restoring testosterone levels by adding dehydroepiandrosterone to a drospirenone containing combined oral contraceptive: II. Clinical effects.
    Zimmerman Y, Foidart JM, Pintiaux A, Minon JM, Fauser BC, Cobey K, Coelingh Bennink HJ.
    Contraception; 2015 Feb; 91(2):134-42. PubMed ID: 25496917
    [Abstract] [Full Text] [Related]

  • 6. Novel ethinyl estradiol-beta-cyclodextrin clathrate formulation does not influence the relative bioavailability of ethinyl estradiol or coadministered drospirenone.
    Blode H, Schürmann R, Benda N.
    Contraception; 2008 Mar; 77(3):171-6. PubMed ID: 18279686
    [Abstract] [Full Text] [Related]

  • 7. Transfer of drospirenone to breast milk after a single oral administration of 3 mg drospirenone + 30 microg ethinylestradiol to healthy lactating women.
    Blode H, Foidart JM, Heithecker R.
    Eur J Contracept Reprod Health Care; 2001 Sep; 6(3):167-71. PubMed ID: 11763981
    [Abstract] [Full Text] [Related]

  • 8. A historical cycle control comparison of two drospirenone-containing combined oral contraceptives: ethinylestradiol 30 μg/drospirenone 3 mg administered in a 21/7 regimen versus ethinylestradiol 20 μg/drospirenone 3 mg administered in a 24/4 regimen.
    Marr J, Gerlinger C, Kunz M.
    Eur J Obstet Gynecol Reprod Biol; 2012 May; 162(1):91-5. PubMed ID: 22391750
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of 3 mg drospirenone/20 mcg ethinylestradiol oral contraceptive administered in 24/4 regimen in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled trial.
    Koltun W, Lucky AW, Thiboutot D, Niknian M, Sampson-Landers C, Korner P, Marr J.
    Contraception; 2008 Apr; 77(4):249-56. PubMed ID: 18342647
    [Abstract] [Full Text] [Related]

  • 10. A combined oral contraceptive containing 3-mg drospirenone/ 20-microg ethinyl estradiol in the treatment of acne vulgaris: a randomized, double-blind, placebo-controlled study evaluating lesion counts and participant self-assessment.
    Lucky AW, Koltun W, Thiboutot D, Niknian M, Sampson-Landers C, Korner P, Marr J.
    Cutis; 2008 Aug; 82(2):143-50. PubMed ID: 18792547
    [Abstract] [Full Text] [Related]

  • 11. Characterisation of the pharmacokinetics of ethinylestradiol and drospirenone in extended-cycle regimens: population pharmacokinetic analysis from a randomised Phase III study.
    Reif S, Snelder N, Blode H.
    J Fam Plann Reprod Health Care; 2013 Apr; 39(2):e1-13. PubMed ID: 23493606
    [Abstract] [Full Text] [Related]

  • 12. Comparative pharmacokinetic estimates of drospirenone alone and in combination with ethinyl estradiol after single and repeated oral administration in healthy females.
    Richter WH, Koytchev R, Kirkov V, Merki G, Colli E, Regidor PA.
    Contraception; 2020 Feb; 101(2):137-143. PubMed ID: 31758920
    [Abstract] [Full Text] [Related]

  • 13. Effects of oral contraceptives containing ethinylestradiol with either drospirenone or levonorgestrel on various parameters associated with well-being in healthy women: a randomized, single-blind, parallel-group, multicentre study.
    Kelly S, Davies E, Fearns S, McKinnon C, Carter R, Gerlinger C, Smithers A.
    Clin Drug Investig; 2010 Feb; 30(5):325-36. PubMed ID: 20384388
    [Abstract] [Full Text] [Related]

  • 14. The effect of 2 combined oral Contraceptives containing either drospirenone or cyproterone acetate on acne and seborrhea.
    van Vloten WA, van Haselen CW, van Zuuren EJ, Gerlinger C, Heithecker R.
    Cutis; 2002 Apr; 69(4 Suppl):2-15. PubMed ID: 12096825
    [Abstract] [Full Text] [Related]

  • 15. Ovulatory effects of three oral contraceptive regimens: a randomized, open-label, descriptive trial.
    Seidman L, Kroll R, Howard B, Ricciotti N, Hsieh J, Weiss H.
    Contraception; 2015 Jun; 91(6):495-502. PubMed ID: 25746294
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of the effect of a new oral contraceptive containing estetrol and drospirenone on hemostasis parameters.
    Douxfils J, Klipping C, Duijkers I, Kinet V, Mawet M, Maillard C, Jost M, Rosing J, Foidart JM.
    Contraception; 2020 Dec; 102(6):396-402. PubMed ID: 32956694
    [Abstract] [Full Text] [Related]

  • 17. Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive.
    Keam SJ, Wagstaff AJ.
    Treat Endocrinol; 2003 Dec; 2(1):49-70. PubMed ID: 15871554
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics of drospirenone and ethinylestradiol in Caucasian and Japanese women.
    Blode H, Kowal K, Roth K, Reif S.
    Eur J Contracept Reprod Health Care; 2012 Aug; 17(4):284-97. PubMed ID: 22680989
    [Abstract] [Full Text] [Related]

  • 19. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment.
    Thorneycroft lH, Gollnick H, Schellschmidt I.
    Cutis; 2004 Aug; 74(2):123-30. PubMed ID: 15379365
    [Abstract] [Full Text] [Related]

  • 20. Endocrine and metabolic effects of an oral contraceptive containing estetrol and drospirenone.
    Klipping C, Duijkers I, Mawet M, Maillard C, Bastidas A, Jost M, Foidart JM.
    Contraception; 2021 Apr; 103(4):213-221. PubMed ID: 33428907
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.